Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete 2024-12-19 17:02
First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients 2024-11-28 17:22
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline 2024-11-19 06:24
Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology 2024-11-13 16:18
Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals 2024-11-04 06:07
Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix® 2024-10-30 21:27
FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent 2024-10-24 06:02
Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals 2024-10-22 18:57
Telix Files Form 20-F Registration Statement for Nasdaq ADS 2024-10-18 05:32
Telix Q3 2024 Business Update - Quarterly Revenue Exceeds AU$200M 2024-10-17 15:54
Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy 2024-10-08 04:00
First Patient Dosed in Phase II 'CA-NINE' Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery 2024-10-04 04:00
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform 2024-09-23 07:38
Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix® 2024-09-18 05:00
'Highly Accurate': Telix's Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology 2024-09-11 06:46
IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances 2024-09-04 06:57
Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent 2024-08-28 07:53
Telix Announces Reorganisation to Deliver on Strategic Priorities 2024-08-27 07:15
Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities 2024-08-22 17:04
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent 2024-07-24 08:10
1 2 3 4 5 7